Amyloidose er en sygdom med mange ansigter

Magne B. L. Spanggaard; Charlotte Toftmann Hansen; Michael  Maiborg; Aleksandra Maria Rojek; Sys Vestergaard; Hans Christian Beck; Hanne E. H. Møller; Niels Abildgaard

Amyloidose er en sygdom med mange ansigter

Translated title of the contribution: Amyloidosis is a disease with many faces

Magne B. L. Spanggaard, Charlotte Toftmann Hansen, Michael Maiborg, Aleksandra Maria Rojek, Sys Vestergaard, Hans Christian Beck, Hanne E. H. Møller, Niels Abildgaard^*

^*Corresponding author for this work

Odense University Hospital

Research output: Contribution to journal › Journal article › Research › peer-review

12 Downloads (Pure)

Abstract

Amyloidosis is a severe disease caused by protein misfolding and deposition in tissues and organs. Thirty-eight different proteins are known to be amyloidogenic. Amyloidosis is categorized into inherited or acquired, and systemic or localized. Light‐chain (AL)- and transthyretin (ATTR) amyloidosis are the two most common subtypes. Awareness, early diagnosis, accurate subtyping and relevant treatment are crucial for the management. Novel therapies of systemic AL and ATTR amyloidosis have considerably improved outcome and survival. The aim of this review is to increase awareness and knowledge on diagnosing amyloidosis.

Translated title of the contribution	Amyloidosis is a disease with many faces
Original language	Danish
Article number	V08220479
Journal	Ugeskrift for Læger
Volume	185
Issue number	8
Pages (from-to)	770-774
ISSN	0041-5782
Publication status	Published - 17. Apr 2023

Documents & Links

Open Access VersionFinal published version, 1.01 MBLicence: CC BY-NC-ND

https://ugeskriftet.dk/videnskab/amyloidose-er-en-sygdom-med-mange-ansigterLicence: CC BY-NC-ND

Cite this

@article{da02c67f70dc4fe2aad210910c3f03db,

title = "Amyloidose er en sygdom med mange ansigter",

abstract = "Amyloidosis is a severe disease caused by protein misfolding and deposition in tissues and organs. Thirty-eight different proteins are known to be amyloidogenic. Amyloidosis is categorized into inherited or acquired, and systemic or localized. Light‐chain (AL)- and transthyretin (ATTR) amyloidosis are the two most common subtypes. Awareness, early diagnosis, accurate subtyping and relevant treatment are crucial for the management. Novel therapies of systemic AL and ATTR amyloidosis have considerably improved outcome and survival. The aim of this review is to increase awareness and knowledge on diagnosing amyloidosis.",

author = "Spanggaard, {Magne B. L.} and Hansen, {Charlotte Toftmann} and Michael Maiborg and Rojek, {Aleksandra Maria} and Sys Vestergaard and Beck, {Hans Christian} and M{\o}ller, {Hanne E. H.} and Niels Abildgaard",

year = "2023",

month = apr,

day = "17",

language = "Dansk",

volume = "185",

pages = "770--774",

journal = "Ugeskrift for L{\ae}ger",

issn = "0041-5782",

publisher = "Almindelige Danske Laegeforening",

number = "8",

}

TY - JOUR

T1 - Amyloidose er en sygdom med mange ansigter

AU - Spanggaard, Magne B. L.

AU - Hansen, Charlotte Toftmann

AU - Maiborg, Michael

AU - Rojek, Aleksandra Maria

AU - Vestergaard, Sys

AU - Beck, Hans Christian

AU - Møller, Hanne E. H.

AU - Abildgaard, Niels

PY - 2023/4/17

Y1 - 2023/4/17

N2 - Amyloidosis is a severe disease caused by protein misfolding and deposition in tissues and organs. Thirty-eight different proteins are known to be amyloidogenic. Amyloidosis is categorized into inherited or acquired, and systemic or localized. Light‐chain (AL)- and transthyretin (ATTR) amyloidosis are the two most common subtypes. Awareness, early diagnosis, accurate subtyping and relevant treatment are crucial for the management. Novel therapies of systemic AL and ATTR amyloidosis have considerably improved outcome and survival. The aim of this review is to increase awareness and knowledge on diagnosing amyloidosis.

AB - Amyloidosis is a severe disease caused by protein misfolding and deposition in tissues and organs. Thirty-eight different proteins are known to be amyloidogenic. Amyloidosis is categorized into inherited or acquired, and systemic or localized. Light‐chain (AL)- and transthyretin (ATTR) amyloidosis are the two most common subtypes. Awareness, early diagnosis, accurate subtyping and relevant treatment are crucial for the management. Novel therapies of systemic AL and ATTR amyloidosis have considerably improved outcome and survival. The aim of this review is to increase awareness and knowledge on diagnosing amyloidosis.

M3 - Tidsskriftartikel

C2 - 36629291

SN - 0041-5782

VL - 185

SP - 770

EP - 774

JO - Ugeskrift for Læger

JF - Ugeskrift for Læger

IS - 8

M1 - V08220479

ER -

Amyloidose er en sygdom med mange ansigter

Abstract

Documents & Links

Fingerprint

Cite this